InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
-15.4%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Werner Milton H., Chairman & CEO. Insider active across 2 companies, notably Inhibikase Therapeutics, Inc.. Aggregated, 7 disclosures have been published. Breakdown: 4 buys · 0 sell. Total volume traded: €45k. Activity tracked since 14 May 2021. The latest transaction was disclosed on 16 August 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Werner Milton H.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
5,000 shares@ US$0.802.6% of flowCommon StockSEC:0000899243-22-028794:0
Canonical exit: 14 Nov 2022 (T+90)
5,000 shares@ US$0.9760.0020% mcap3.1% of flowCommon StockSEC:0000899243-22-020094:0
Canonical exit: 25 Aug 2022 (T+90)
10,000 shares@ US$0.600.0025% mcap3.9% of flowCommon StockSEC:0000899243-22-019229:0
Canonical exit: 18 Aug 2022 (T+90)
21,853 shares@ US$2.0228.7% of flowCommon StockSEC:0001104659-22-001168:0
17,569 shares@ US$1.9822.7% of flowCommon StockSEC:0001104659-21-141628:0
Canonical exit: 15 Feb 2022 (T+90)
21,853 shares@ US$2.0227.9% of flowCommon StockSEC:0000899243-21-033598:0
43,707 shares@ US$0.3810.2% of flowCommon StockSEC:0000899243-21-019788:0
7 of 7 declarations
About Werner Milton H.
Milton H. Werner is the President and CEO of Inhibikase Therapeutics, Inc. He leads the company with a strategic vision, overseeing operations and research and development initiatives. Milton is responsible for implementing corporate strategies and managing stakeholder relationships. His experience in the biopharmaceutical sector is a valuable asset for the leadership of Inhibikase.
